Clinical-grade RAS inhibitors raise an unresolved question as to whether KRAS alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, we compared resistance mechanisms between KRASG12D and KRASG12R, mutants with fundame...
Daniel Dorbin, Julia R. Herrera, R. Davidson et al.· Cancer Research· 1 citation· ⚡1
Abstract Background CYLD , a tumor suppressor gene encoding a deubiquitinase enzyme, regulates tumorigenesis via NF-κB signaling. CYLD mutations are linked to immune evasion and PD-L1 upregulation, particularly in virus-associated cancers. We evaluated CYLD alterations across cancers and their correlation with PD-L1 ex...
U. Dişel, S. Sisoudiya, S. Sivakumar et al.· Research Square· 0 citations
Clinical-grade RAS(ON) inhibitors have transformed treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), but acquired resistance is universal and post-progression treatment selection remains empiric. Whether specific KRAS alleles impose distinct constraints on the adaptive resistance network, and whet...
T. McFall, Daniel Dorbin, Julia R. Herrera et al.· Cancer Research· 0 citations
A narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured.
Farhood Farahnak, W. El-Deiry, Yves A. Lussier et al.· JCO Global Oncology· 0 citations
Rare cancers have challenged conventional drug development because patient populations are too small for traditional disease-specific trials. Yet rare cancers may provide the paradigm for the future of oncology. Cancer classification has evolved from organ-of-origin taxonomy to molecular stratification and then t...
R. Kurzrock· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
